<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="323">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01163526</url>
  </required_header>
  <id_info>
    <org_study_id>HEP0031</org_study_id>
    <secondary_id>SU-07092010-6491</secondary_id>
    <nct_id>NCT01163526</nct_id>
  </id_info>
  <brief_title>Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies</brief_title>
  <official_title>Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Siemens Healthcare Sector</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether baseline CT perfusion characteristics
      (measurements of blood-flow using CT) of hepatic cancers can predict tumor response to
      treatment and whether perfusion CT after treatment can be used as a biomarker for response
      to treatment. Treatment may consist of chemotherapy or stereotactic body radiotherapy
      (SBRT)or embolization therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Predict RECIST response to treatment</measure>
    <time_frame>at 3 months from CT perfusion  parameters before and after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize CT perfusion longitudinally in both responders and nonresponders</measure>
    <time_frame>1 yr</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predict disease progression</measure>
    <time_frame>1 yr</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Brain (Nervous System) Cancers</condition>
  <condition>Colon/Rectal Cancer</condition>
  <condition>Colon Cancer</condition>
  <condition>Hepatobiliary Cancers</condition>
  <condition>Hepatocellular Carcinoma (Hepatoma)</condition>
  <condition>Liver</condition>
  <arm_group>
    <arm_group_label>neuroendocrine metastases</arm_group_label>
    <description>15 patients with neuroendocrine metastases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>colon cancer metastases</arm_group_label>
    <description>15 patients with colon cancer metastases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCC treated with cyberknife radiation and chemotherapy</arm_group_label>
    <description>15 patients with HCC treated with cyberknife radiation and chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCC treated with Sirsphere embolization and chemotherapy</arm_group_label>
    <description>15 patients with HCC treated with Sirsphere embolization and chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CT perfusion</intervention_name>
    <arm_group_label>neuroendocrine metastases</arm_group_label>
    <arm_group_label>colon cancer metastases</arm_group_label>
    <arm_group_label>HCC treated with cyberknife radiation and chemotherapy</arm_group_label>
    <arm_group_label>HCC treated with Sirsphere embolization and chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients must be 18 years or older.  Patients must not be pregnant and, if of
        child-bearing age, must take precautions not to become pregnant.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:3.1.1 Patients with suspected or biopsy-proven liver masses including
        unresectable hepatocellular carcinoma (HCC), unresectable colon cancer metastases to the
        liver, and metastatic neuroendocrine tumors to the liver will be eligible for enrollment.

        3.1.2  Patients who have undergone prior chemotherapy more than one year prior to the
        study are eligible for enrollment.

        3.1.4 Patients must be 18 years or older.  Patients must not be pregnant and, if of
        child-bearing age, must take precautions not to become pregnant.

        3.1.5 No life expectancy restrictions.

        3.1.6 ECOG and Karnofsky Performance Status will not be employed.

        3.1.7 Patients with renal failure are ineligible for this study (Glomerular filtration
        rate (GFR) must be &gt; 60)

        3.1.8 Ability to understand and willingness to sign a written informed consent document.

        Exclusion Criteria:3.2.1 Patients who have undergone prior chemoembolization of
        hepatocellular carcinoma (HCC) are ineligible for enrollment.  Patients who have undergone
        chemotherapy within one year prior to the study are also ineligible for enrollment.

        3.2.2 No restrictions regarding use of other investigational agents.

        3.2.3 Patients with severe contrast allergy are ineligible.

        3.2.4 Patients who are pregnant or are trying to become pregnant are excluded from this
        study.

        3.2.5 Patients who are cancer survivors or Human Immunodeficiency Virus (HIV)-positive
        will not be excluded.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aya Kamaya</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Euodia Jonathan</last_name>
      <phone>650-723-7419</phone>
      <email>euodia@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cancer Clinical Trials Office</last_name>
      <phone>(650) 498-7061</phone>
    </contact_backup>
    <investigator>
      <last_name>Aya Kamaya</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juergen Karl Willmann</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samuel So</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr. John D Louie</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pamela Kunz</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nishita N. Kothary</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Albert Koong</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominik Fleischmann</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>George Albert Fisher M.D. Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cheryl Cho-Phan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel T Chang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 9, 2013</lastchanged_date>
  <firstreceived_date>July 14, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
